ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Oncology and Hematology News and Journal Articles

Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise

Phillip L. Palmbos, MD, PhD, and Maha H. Hussain, MD
This article will review how PARP inhibitors function as a class, review the molecular features that sensitize cancer cells to this therapy, and discuss the data supporting its potential for patients with prostate cancer.

Recent Content

Young adult female cancer survivors have unmet informational needs regarding reproductive issues and decisional conflict regarding fertility preservation.

The incidence of cardiovascular events is reduced with increasing physical activity among women with nonmetastatic breast cancer.

A new study has suggested two new ways to report on adverse events in the era of molecularly targeted therapies.

A phase II trial found that cabozantinib offers significantly better progression-free survival over sunitinib in patients with untreated advanced RCC.

People who carry a germline breast cancer susceptibility mutation can still substantially lower their risk of developing breast cancer, according to a new study.

This acute lymphocytic leukemia (ALL) slide show features blood smears showing mature and immature lymphocytes, and bone marrow biopsies with ALL involvement.

The higher incidence of bladder cancer in the Northeast in the last 50 years may be attributed to the presence of arsenic in the drinking water, according to a new study.

By clicking Accept, you agree to become a member of the UBM Medica Community.